SUMMARY
Maternal and umbilical venous serum naloxone concentrations were measured after the i.v. (30 mothers) or i.m. (seven mothers) injection of naloxone 400ug. Following i.v. naloxone there was rapid transfer to the fetus and therapeutic plasma concentrations could be expected in 1 or 2 min. However, following i.m. administration, neonatal concentrations were variable. In five non-pregnant volunteers naloxone 400 fig i. v. resulted in concentrations greater than 2.5 ng ml-1 for up to 30 min. After naloxone 2 mg i.m., a peak was reached at 10 min, followed by slow clearance over several hours.
Each mother received a single dose of naloxone 400 ug i.v. or i.m. during the second stage of labour and was offered 50% nitrous oxide in oxygen (Entonox) for self administration as desired. The time interval between the administration of the naloxone and the clamping of the umbilical cord was noted. Samples of umbilical venous blood and maternal venous blood were taken immediately into heparinized and plain syringes. The pH, Pco 2 , and Po 2 of umbilical venous blood were estimated, but only relevant pH results are reported here.
Five non-pregnant adult volunteers (65-75 kg) received a single dose of naloxone 400 ug i.v. On a subsequent occasion at least 1 week later, naloxone 2 mg was administered i.m. On each occasion blood samples were taken at intervals between 1 min and 48 h.
Serum samples were stored at -20 °C for subsequent measurements of serum naloxone concentrations by radioimmunoassay (Berkowitz et al., 1975) . The lower limit of sensitivity for the assay, using 50-ul samples, was 0.02 ng ml" 1 .
RESULTS

Pregnant patients
Intravenous route. Thirty mothers were studied at intervals of 1-29 min before cord clamping (table I) .
All except two babies were in good clinical condition at birth. The two exceptions had 1-min Apgar scores of 5 and 6, but both had scores of 10 at 5 min. Cord blood pH values were 7.24 and 7.33, respectively.
The mean maternal serum concentration of naloxone in non-haemolysed samples was 5.8 ng ml" 1 (range 2.0-13.8). There was a wide scatter of concentrations in relation to time, but the highest concentrations were found in the period 2-10 min after injection.
The fetal results showed a similar pattern, but with lower overall values: mean 2.9 ng ml" 1 (range 0.175-7.9).
Intramuscular route. Seven mothers were given naloxone 5-31 min before cord clamping (table  II) . All the babies except one were in good condition at birth. The exceptional baby had a 1 -min Apgar score of 4, with a cord blood pH of 7.3.
The mean maternal serum concentration of naloxone was 2.8 ng ml" 1 (range 1.24-6.0) and the mean umbilical vein concentration was 1.04 ng ml" 1 (range up to 3.8). In two patients the concentration was below the lower limit of sensitivity of the assay (0.02 ng ml" 1 ).
Non-pregnant subjects
Intravenous route ( fig. 1) . At 1 min after the administration of naloxone 400 ng, the mean serum concentration was 146.3 ng ml" 1 (SEM 23.8) and had decreased to 3.6 ng ml" 1 (SEM 0.2) by 30 min.
Intramuscular route ( fig. 1 ). At 10 min after injection of naloxone 2 mg, a peak concentration of 36.7 ng ml" 1 (SEM 3.9) was achieved, which then decreased slowly to 6.4 ng ml" 1 (SEM 0.5) by 4 h, and 3.4 ng ml" 1 (SEM 0.8) by 8 h. Concentrations were still in the measurable range at 48 h.
DISCUSSION
The therapeutically effective serum concentration of naloxone is not known with certainty and there are no data relating serum concentrations to the effect in the neonate. In a study in which naloxone 50 jig kg" 1 was given i.v. to subjects with morphine-induced respiratory depression, reversal was waning after 30 min (Evans, Hogg and Rosen, 1976). In the neonates studied by Wiener, Hogg and Rosen (1977) , who received naloxone 60 (ig kg" 1 i.m., reversal of pethidine-induced respiratory depression could be demonstrated within 30 min and lasted for up to 48 h. No measurements of naloxone concentrations were made in either study.
Our study in non-pregnant volunteers suggests that the normal therapeutic dose of naloxone (400 (ig-approximately 5.7 ug kg" 1 )administered i.v. produces serum concentrations greater than 3 ng ml" 1 for at least 30 min. In the present study only three of the mothers who received naloxone 400 |ig i.v. between 1 and 29 min before blood sampling had concentrations less than 3 ng ml" 1 (at 10, 20, and 28 min, respectively), and all the maternal concentrations were greater than 2.5 ng ml" 1 . At least part of this difference is likely to be the result of differences in volume distribution between pregnant and non-pregnant subjects.
The neonatal samples in our i.v. study were, with one exception in which the fetal sample was haemolysed, below these maternal values and almost half were less than 2.5 ng ml" 1 . However, naloxone clearly crosses the placental barrier easily and rapidly, so that some therapeutic effect could be anticipated in most babies, even with the dose used in this study. If the maternal dose was increased to naloxone 600 ng, 87 % of babies would be expected to have values greater than 2.5 ng ml" 1 .
The naloxone concentrations in non-pregnant volunteers after a dose of approximately 30 (ig kg" 1 i.m., were considerably greater than 2.5 ng ml" 1 and decreased slowly over a period of several hours. As the plasma half-life of naloxone in the neonate (3 h) (Moreland et al., 1980) is twice as long as in the adult (Berkowitz, 1976) , a prolonged duration of action in the neonate could be anticipated if satisfactory concentrations could be achieved initially. However, the placental transfer following the i.m. injection of 400 ug to the mother was too variable to be acceptable for therapeutic purposes. From the available data it is not possible to be certain whether a large dose would consistently result in adequate concentrations in the fetus, but this could be determined by more extensive studies.
It is more logical to administer naloxone to the baby after birth, according to need, and that is our current practice. However, there are situations in which evidence of fetal compromise in a mother who has also received narcotic analgesia, usually pethidine, may lead to anxiety about the fetal/neonatal adaptive responses at delivery. In such circumstances the maternal administration of naloxone 600 ng i.v. might be a satisfactory option.
